^
Association details:
| Biomarker: | PIK3R1 mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Piqray (alpelisib) (PIK3CA inhibitor) + tilarginine (L-NMMA) (pan-NOS inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3447 - NOS inhibition reverses epithelial-to-mesenchymal transition and synergizes with alpelisib in metaplastic breast cancer
Published date:
03/15/2023
Excerpt:
L-NMMA was synergistic with alpelisib in MpBC cell lines with PIK3CA/PIK3R1 mutations…. In vivo evaluation using MpBC PDX tumors found that L-NMMA augmented the efficacy of alpelisib in reducing tumor volume in PIK3CA-mutated MpBC PDX models….We find that combining L-NMMA and alpelisib is a novel therapeutic strategy to treat MpBC...
Source:
Title:
NOS inhibition reverses epithelial-to-mesenchymal transition and synergizes with alpelisib in metaplastic breast cancer
Published date:
11/22/2022
Excerpt:
Combining L-NMMA with alpelisib was synergistic in MpBC cell lines harboring PIK3CA/PIK3R1 mutations (CI< 1)….In vivo evaluation using MpBC PDX tumors found that L-NMMA significantly augmented the efficacy of alpelisib in reducing tumor volume in PIK3CA-mutated MpBC PDX models.
